CNSX:ATT - Abattis Bioceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0 (0.00%)

This chart shows the closing price for ATT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abattis Bioceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATT

Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for Abattis Bioceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for ATT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Abattis Bioceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2018Fundamental ResearchInitiated CoverageBuy$0.30
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Abattis Bioceuticals

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

1,420,000 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abattis Bioceuticals?

The following Wall Street analysts have issued stock ratings on Abattis Bioceuticals in the last year:
View the latest analyst ratings for ATT.

What is the current price target for Abattis Bioceuticals?

0 Wall Street analysts have set twelve-month price targets for Abattis Bioceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Abattis Bioceuticals in the next year.
View the latest price targets for ATT.

What is the current consensus analyst rating for Abattis Bioceuticals?

Abattis Bioceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ATT.

What other companies compete with Abattis Bioceuticals?

How do I contact Abattis Bioceuticals' investor relations team?

Abattis Bioceuticals' physical mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company's listed phone number is +1-604-3360881. The official website for Abattis Bioceuticals is www.abattis.com. Learn More about contacing Abattis Bioceuticals investor relations.